These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 38634685)
1. Influence of further decompensation on survival across clinical stages of decompensated cirrhosis: The role of portal hypertension and HVPG changes. Garcia-Guix M; Ardevol A; Sapena V; Alvarado-Tápias E; Huertas A; Brujats A; Fajardo J; Cuyas B; Poca M; Guarner C; Torras X; Escorsell À; Villanueva C Liver Int; 2024 Aug; 44(8):1971-1989. PubMed ID: 38634685 [TBL] [Abstract][Full Text] [Related]
3. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding. Villanueva C; Aracil C; Colomo A; Hernández-Gea V; López-Balaguer JM; Alvarez-Urturi C; Torras X; Balanzó J; Guarner C Gastroenterology; 2009 Jul; 137(1):119-28. PubMed ID: 19344721 [TBL] [Abstract][Full Text] [Related]
4. The portal hypertension syndrome: etiology, classification, relevance, and animal models. Bosch J; Iwakiri Y Hepatol Int; 2018 Feb; 12(Suppl 1):1-10. PubMed ID: 29064029 [TBL] [Abstract][Full Text] [Related]
5. Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis. Alvarado-Tapias E; Ardevol A; Garcia-Guix M; Montañés R; Pavel O; Cuyas B; Graupera I; Brujats A; Vilades D; Colomo A; Poca M; Torras X; Guarner C; Concepción M; Aracil C; Torres F; Villanueva C J Hepatol; 2020 Oct; 73(4):829-841. PubMed ID: 32298768 [TBL] [Abstract][Full Text] [Related]
6. New concepts on the clinical course and stratification of compensated and decompensated cirrhosis. D'Amico G; Morabito A; D'Amico M; Pasta L; Malizia G; Rebora P; Valsecchi MG Hepatol Int; 2018 Feb; 12(Suppl 1):34-43. PubMed ID: 28681347 [TBL] [Abstract][Full Text] [Related]
7. The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. Paternostro R; Becker J; Hofer BS; Panagl V; Schiffke H; Simbrunner B; Semmler G; Schwabl P; Scheiner B; Bucsics T; Bauer D; Binter T; Trauner M; Mandorfer M; Reiberger T Dig Liver Dis; 2022 Apr; 54(4):500-508. PubMed ID: 34799282 [TBL] [Abstract][Full Text] [Related]
8. Use of non-selective beta blockers in cirrhosis: the evidence we need before closing (or not) the window. La Mura V; Tosetti G; Primignani M; Salerno F World J Gastroenterol; 2015 Feb; 21(8):2265-8. PubMed ID: 25741132 [TBL] [Abstract][Full Text] [Related]
9. Improving primary prophylaxis of variceal bleeding by adapting therapy to the clinical stage of cirrhosis. A competing-risk meta-analysis of individual participant data. Villanueva C; Sapena V; Lo GH; Seo YS; Shah HA; Singh V; Tripathi D; Schepke M; Gheorghe C; Bonilha DQ; Jutabha R; Wang HM; Rodrigues SG; Brujats A; Lee HA; Azam Z; Kumar P; Hayes PC; Sauerbruch T; Chen WC; Iacob S; Libera ED; Jensen DM; Alvarado E; Torres F; Bosch J; Aliment Pharmacol Ther; 2024 Feb; 59(3):306-321. PubMed ID: 38108646 [TBL] [Abstract][Full Text] [Related]
10. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Zipprich A; Garcia-Tsao G; Rogowski S; Fleig WE; Seufferlein T; Dollinger MM Liver Int; 2012 Oct; 32(9):1407-14. PubMed ID: 22679906 [TBL] [Abstract][Full Text] [Related]
12. Prognostic markers in patients with cirrhosis and portal hypertension who have not bled. Poca M; Puente A; Graupera I; Villanueva C Dis Markers; 2011; 31(3):147-54. PubMed ID: 22045400 [TBL] [Abstract][Full Text] [Related]
14. Development of ascites in compensated cirrhosis with severe portal hypertension treated with β-blockers. Hernández-Gea V; Aracil C; Colomo A; Garupera I; Poca M; Torras X; Miñana J; Guarner C; Villanueva C Am J Gastroenterol; 2012 Mar; 107(3):418-27. PubMed ID: 22334252 [TBL] [Abstract][Full Text] [Related]
15. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Villanueva C; Albillos A; Genescà J; Garcia-Pagan JC; Calleja JL; Aracil C; Bañares R; Morillas RM; Poca M; Peñas B; Augustin S; Abraldes JG; Alvarado E; Torres F; Bosch J Lancet; 2019 Apr; 393(10181):1597-1608. PubMed ID: 30910320 [TBL] [Abstract][Full Text] [Related]
16. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Reiberger T; Ulbrich G; Ferlitsch A; Payer BA; Schwabl P; Pinter M; Heinisch BB; Trauner M; Kramer L; Peck-Radosavljevic M; Gut; 2013 Nov; 62(11):1634-41. PubMed ID: 23250049 [TBL] [Abstract][Full Text] [Related]
17. Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis. Reiberger T; Ferlitsch A; Payer BA; Pinter M; Homoncik M; Peck-Radosavljevic M; J Gastroenterol; 2012 May; 47(5):561-8. PubMed ID: 22170417 [TBL] [Abstract][Full Text] [Related]
18. Hepatic venous pressure gradient and outcomes in cirrhosis. Ripoll C J Clin Gastroenterol; 2007; 41 Suppl 3():S330-5. PubMed ID: 17975485 [TBL] [Abstract][Full Text] [Related]
19. A Prognostic Strategy Based on Stage of Cirrhosis and HVPG to Improve Risk Stratification After Variceal Bleeding. La Mura V; Garcia-Guix M; Berzigotti A; Abraldes JG; García-Pagán JC; Villanueva C; Bosch J Hepatology; 2020 Oct; 72(4):1353-1365. PubMed ID: 31960441 [TBL] [Abstract][Full Text] [Related]